Dec 24 (Reuters) - The U.S. Food and Drug Administration has approved Omeros' OMER.O drug for a dangerous transplant complication, marking the first treatment to be greenlit for the condition, the company said on Wednesday.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.